Alternative NSN: 6505-01-124-5361 |
Item Name: Maprotiline Hydrochloride Tablet |
NIIN: 011245361 |
NCB Code: USA (01) |
Manufacturers: Ciba Geigy Corp, Mylan Pharmaceuticals Inc |
Are you looking for NSN 6505-01-124-5361 - Maprotiline Hydrochloride Tablet parts? We can help! Simply complete the RFQ form given below to get started. The National Stock Number (NSN) is a 13-digit serial number assigned by the US Defense Logistics Agency (DLA) to items that are procured, stocked, and issued through the federal supply system. Parts under NSN 6505-01-124-5361 is 1720, NDC00083-0026-30, NDC00378-0087-01 from manufacturer Ciba Geigy Corp, Mylan Pharmaceuticals Inc. Use our optimized search engine to find your required part—then submit an instant RFQ for a quick, competitive quote. Here at Aviation Orbit, we make your purchasing process as simple and efficient as possible.
Part No | Manufacturer | Item Name | QTY | RFQ |
---|---|---|---|---|
1720 | Ciba Geigy Corp | maprotiline hydrochloride tablet | Avl | RFQ |
NDC00083-0026-30 | Ciba Geigy Corp | maprotiline hydrochloride tablet | Avl | RFQ |
NDC00378-0087-01 | Mylan Pharmaceuticals Inc | maprotiline hydrochloride tablet | Avl | RFQ |
MRC | Criteria | Characteristic |
---|---|---|
AKJA | ACTIVE MEDICAMENT MEDICINAL STRENGTH | 50.000 MILLIGRAMS MAPROTILINE HYDROCHLORIDE ACTIVE INGREDIENT |
CQCT | PRIMARY CONTAINER TYPE | BOTTLE |
CRLK | PRIMARY CONTAINER CONTENT QUANTITY | 100.000 TABLETS |
CXCY | PART NAME ASSIGNED BY CONTROLLING AGENCY | MAPROTILINE HYDROCHLORIDE TABLETS 50MG 100S BT |
6550-01-678-7204 (6550016787204) |
6550-01-678-6938 (6550016786938) |
6550-01-677-7355 (6550016777355) |
6550-01-677-5960 (6550016775960) |
6550-01-677-5895 (6550016775895) |
6550-01-677-2512 (6550016772512) |
6550-01-675-9034 (6550016759034) |
6550-01-674-7273 (6550016747273) |
6550-01-674-7271 (6550016747271) |
6550-01-671-9301 (6550016719301) |
6550-01-671-9115 (6550016719115) |
6550-01-671-4950 (6550016714950) |
We Hope You Choose Us as Your Low-Price, High-Quality Parts Distributor In the Future.
Request for Quote